August 14th 2025
The newly developed model has an area under the curve of 0.807 for predicting progression-free survival.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
1 Credit / Cardiology, Neurology
View More
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
View More
Oncology Value Coalition: Disparities in Cancer Care—Sources and Solutions, Part 2
April 22nd 2021In the inaugural Oncology Value Coalition from The American Journal of Managed Care®, Kashyap Patel, MD, led a discussion with Debra Patt, MD, PhD, MBA; and Karen Winkfield, MD, PhD, exploring findings that suggest minority groups develop cancer at higher rates and experience worse outcomes than nonminority groups.
Read More
Oncology Value Coalition: Disparities in Cancer Care—Sources and Solutions, Part 1
April 22nd 2021In the inaugural Oncology Value Coalition from The American Journal of Managed Care®, Kashyap Patel, MD, led a discussion with Debra Patt, MD, PhD, MBA; and Karen Winkfield, MD, PhD, exploring findings that suggest minority groups develop cancer at higher rates and experience worse outcomes than nonminority groups.
Read More
Treatment Patterns for Patients With Advanced/Metastatic Cancers by Site of Care
Treatment patterns and overall survival were similar regardless of site of care between patients receiving anticancer therapy in the hospital outpatient vs physician office setting.
Read More
Dr Russell Langan Details Workflow for Cloud-Based Technology to Manage Pancreatic Cancer
April 11th 2021Russell Langan, MD, chief of Surgical Oncology and Hepatopancreatobiliary Surgery at Saint Barnabas Medical Center discusses the workflow of a cloud-based data management platform for patients with pancreatic cysts.
Watch
NCCN Panel Discusses Challenges, Potential Solutions for Racial Disparities in Cancer Care
March 20th 2021A keynote session at the NCCN Virtual Annual Conference brought a panel of patient advocates and experts together for a timely and necessary discussion about strategies to reduce racial disparities in oncology.
Read More
Benefits and Challenges of ePRO Implementation in Oncology
March 19th 2021During a session at the National Comprehensive Cancer Network (NCCN) annual virtual conference, the payer perspective and physician experiences with PRO systems in both the community and academic medical center settings took center stage.
Read More
Cancer Survivors Returning to Work: Barriers and Interventions
March 18th 2021Amye J. Tevaarwerk, MD, director of the Survivorship Program at the University of Wisconsin Carbone Cancer Center, discussed the impact that cancer diagnosis and treatment can have on survivors when it comes to work.
Read More
Oncolytic Virus, CAR T Combination Preclinical Study Shows Activity in Solid Tumors
February 24th 2021Loading chimeric antigen receptor (CAR) T-cells with the oncolytic virus pelareorep improved their efficacy in solid tumor mouse models in a preclinical study presented at the CAR-TCR Summit Europe 2021.
Read More
FDA Approves Cemiplimab for First-Line Advanced NSCLC With PD-L1 Expression
February 22nd 2021The PD-1 inhibitor cemiplimab-rwlc, sold as Libtayo, was FDA approved as a monotherapy for patients with first-line advanced non–small cell lung cancer (NSCLC) with PD-L1 expression of at least 50%.
Read More
Radiation Oncology’s Role in the Next Chapter of Payment Reform
February 18th 2021An ideal alternative payment model would reward radiation oncologists for participation in a value-based payment arrangement that grants them the freedom to make care delivery decisions based on patient needs and in accordance with clinical guidelines, says ASTRO's Anne Hubbard, MBA.
Read More
Cosela Approved for Protection Against Myelosuppression From SCLC Treatment
February 17th 2021The cyclin-dependent kinase 4/6 inhibitor trilaciclib (Cosela) is the first in its class to receive FDA approval as a protective agent against bone marrow loss from treatment for small cell lung cancer (SCLC).
Read More
Amy Ellis: There Was a Big Shift to Telemedicine in Cancer Care Delivery
February 17th 2021With the onset of the pandemic, the increased use of telemedicine has been the biggest change to how cancer care is being delivered; however, whether telemedicine is here to stay depends on the regulators and payers, said Amy Ellis, chief quality officer at Northwest Medical Specialties.
Watch
Amy Ellis on the Benefits of ePROs in Cancer Care
February 3rd 2021Electronic patient-reported outcomes (ePROs) tools can benefit patients by keeping them on treatment longer, and the pandemic has likely accelerated how many practices move to using ePROs, said Amy Ellis, chief quality officer at Northwest Medical Specialties.
Watch
Amy Ellis Discusses Setting Up an ePRO Tool at a Community Cancer Center
January 22nd 2021Setting up a new tool to capture electronic patient-reported outcomes (ePROs) requires a lot of prep work to ensure patients are comfortable and ready to use the tool, said Amy Ellis, chief quality officer at Northwest Medical Specialties.
Watch